AR093671A1 - Anticuerpos monoclonales contra una proteina activada c (apc) - Google Patents
Anticuerpos monoclonales contra una proteina activada c (apc)Info
- Publication number
- AR093671A1 AR093671A1 ARP130104417A ARP130104417A AR093671A1 AR 093671 A1 AR093671 A1 AR 093671A1 AR P130104417 A ARP130104417 A AR P130104417A AR P130104417 A ARP130104417 A AR P130104417A AR 093671 A1 AR093671 A1 AR 093671A1
- Authority
- AR
- Argentina
- Prior art keywords
- apc
- activated protein
- binding
- antibody
- screening
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 101800004937 Protein C Proteins 0.000 abstract 3
- 102000017975 Protein C Human genes 0.000 abstract 3
- 101800001700 Saposin-D Proteins 0.000 abstract 3
- 229960000856 protein c Drugs 0.000 abstract 3
- 230000014508 negative regulation of coagulation Effects 0.000 abstract 2
- 238000012216 screening Methods 0.000 abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 102000010911 Enzyme Precursors Human genes 0.000 abstract 1
- 108010062466 Enzyme Precursors Proteins 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 101710184528 Scaffolding protein Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
En la presente memoria se proporcionan anticuerpos, fragmentos de anticuerpos de unión a antígenos (Fabs) y otras proteínas de andamiaje, dirigidos contra proteína C activada humana (aPC) con unión mínima a su zimógeno de Proteína C (PC). Asimismo, estas proteínas de unión a aPC podrían bloquear potencialmente la actividad anticoagulante de aPC para inducir la coagulación. En la presente memoria se describen los usos terapéuticos de estos unidores así como también los métodos de selección y cribado de anticuerpos específicos. Reivindicación 1: Un anticuerpo monoclonal aislado, en donde dicho anticuerpo se une a proteína C activada e inhibe la actividad anticoagulante pero tiene unión mínima a proteína C no activada, en donde dicho anticuerpo comprende una región variable de cadena pesada que comprende una secuencia de aminoácidos seleccionada entre el grupo que consiste en SEQ ID Nº 14, 15, 17, 18, 19, 21, 22, 23, 109, 111, 113, 115, 117 y 119.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261731294P | 2012-11-29 | 2012-11-29 | |
| US201361786472P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093671A1 true AR093671A1 (es) | 2015-06-17 |
Family
ID=50828462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104417A AR093671A1 (es) | 2012-11-29 | 2013-11-29 | Anticuerpos monoclonales contra una proteina activada c (apc) |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20150307625A1 (es) |
| EP (1) | EP2925351A4 (es) |
| JP (1) | JP2016501230A (es) |
| KR (1) | KR20150088869A (es) |
| CN (1) | CN104812402A (es) |
| AR (1) | AR093671A1 (es) |
| AU (1) | AU2013352159A1 (es) |
| BR (1) | BR112015012414A2 (es) |
| CA (1) | CA2892750A1 (es) |
| HK (1) | HK1212896A1 (es) |
| IL (1) | IL238658A0 (es) |
| MX (1) | MX2015006424A (es) |
| RU (1) | RU2015125349A (es) |
| SG (1) | SG11201503719WA (es) |
| TW (1) | TW201429992A (es) |
| UY (1) | UY35154A (es) |
| WO (1) | WO2014085596A1 (es) |
| ZA (1) | ZA201504659B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077187B2 (en) | 2015-11-17 | 2021-08-03 | Oklahoma Medical Research Foundation | Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof |
| EP3831843A1 (en) | 2019-12-08 | 2021-06-09 | Royal College Of Surgeons In Ireland | A hemostatic agent and uses thereof |
| CN115611986B (zh) * | 2021-07-13 | 2025-08-12 | 上海莱士血液制品股份有限公司 | 针对人活化蛋白c的单克隆抗体及其制备和应用 |
| CN116496394B (zh) * | 2022-01-26 | 2024-07-23 | 东莞市朋志生物科技有限公司 | 抗s100蛋白的抗体、检测s100蛋白的试剂和试剂盒 |
| JP2025509184A (ja) * | 2022-03-04 | 2025-04-11 | コアグラント・セラピューティクス・コーポレイション | 活性化されたタンパク質ｃに対するラクダ科抗体及びその使用 |
| CN118370814A (zh) * | 2023-01-20 | 2024-07-23 | 上海莱士血液制品股份有限公司 | 一种抗aPC单克隆抗体的制剂及其应用 |
| AU2024252640A1 (en) | 2023-04-07 | 2025-10-02 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to activin a receptor like type 1 (alk1) |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993009804A1 (en) * | 1991-11-18 | 1993-05-27 | The Scripps Research Institute | Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation |
| ATE502958T1 (de) * | 1996-04-24 | 2011-04-15 | Univ Michigan | Gegen inaktivierung resistenter faktor viii |
| DE60141844D1 (de) * | 2000-10-02 | 2010-05-27 | Oklahoma Med Res Found | Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen |
| US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| US20030203355A1 (en) * | 2002-04-24 | 2003-10-30 | Los Alamos National Laboratory | Fluorobodies: binding ligands with intrinsic fluorescence |
| GB0309126D0 (en) * | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
| US7329737B2 (en) * | 2004-08-03 | 2008-02-12 | Dyax Corp. | Antibodies that bind hK-1 |
| WO2006067122A2 (en) * | 2004-12-20 | 2006-06-29 | Crucell Holland B.V. | Binding molecules capable of neutralizing west nile virus and uses thereof |
| ES2385054T3 (es) * | 2005-12-13 | 2012-07-17 | Medimmune Limited | Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas |
| US8039597B2 (en) * | 2007-09-07 | 2011-10-18 | Agensys, Inc. | Antibodies and related molecules that bind to 24P4C12 proteins |
| AR068767A1 (es) * | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
| CN101918453A (zh) * | 2007-10-26 | 2010-12-15 | 俄克拉荷马医学研究基金会 | 针对活化蛋白c的单克隆抗体 |
| GB0903151D0 (en) * | 2009-02-25 | 2009-04-08 | Bioinvent Int Ab | Antibody uses and methods |
| US8926976B2 (en) * | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
| GB201011771D0 (en) * | 2010-07-13 | 2010-08-25 | Bioinvent Int Ab | Biological material and particular uses thereof |
| GB201013989D0 (en) * | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
| US20130330353A1 (en) * | 2010-11-16 | 2013-12-12 | Medimmune, Llc | Regimens for treatments using anti-igf antibodies |
| US8440797B2 (en) * | 2010-12-06 | 2013-05-14 | Dainippon Sumitomo Pharma Co., Ltd. | Human monoclonal antibody |
| GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
-
2013
- 2013-11-27 HK HK16100878.9A patent/HK1212896A1/zh unknown
- 2013-11-27 BR BR112015012414A patent/BR112015012414A2/pt not_active IP Right Cessation
- 2013-11-27 SG SG11201503719WA patent/SG11201503719WA/en unknown
- 2013-11-27 CN CN201380062159.XA patent/CN104812402A/zh active Pending
- 2013-11-27 KR KR1020157017008A patent/KR20150088869A/ko not_active Withdrawn
- 2013-11-27 RU RU2015125349A patent/RU2015125349A/ru not_active Application Discontinuation
- 2013-11-27 AU AU2013352159A patent/AU2013352159A1/en not_active Abandoned
- 2013-11-27 EP EP13857869.5A patent/EP2925351A4/en not_active Withdrawn
- 2013-11-27 WO PCT/US2013/072243 patent/WO2014085596A1/en not_active Ceased
- 2013-11-27 US US14/443,710 patent/US20150307625A1/en not_active Abandoned
- 2013-11-27 CA CA2892750A patent/CA2892750A1/en not_active Abandoned
- 2013-11-27 JP JP2015545438A patent/JP2016501230A/ja active Pending
- 2013-11-27 MX MX2015006424A patent/MX2015006424A/es unknown
- 2013-11-28 UY UY0001035154A patent/UY35154A/es not_active Application Discontinuation
- 2013-11-28 TW TW102143366A patent/TW201429992A/zh unknown
- 2013-11-29 AR ARP130104417A patent/AR093671A1/es unknown
-
2015
- 2015-05-06 IL IL238658A patent/IL238658A0/en unknown
- 2015-06-26 ZA ZA2015/04659A patent/ZA201504659B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104812402A (zh) | 2015-07-29 |
| US20150307625A1 (en) | 2015-10-29 |
| WO2014085596A1 (en) | 2014-06-05 |
| EP2925351A4 (en) | 2016-08-24 |
| KR20150088869A (ko) | 2015-08-03 |
| UY35154A (es) | 2014-06-30 |
| MX2015006424A (es) | 2015-08-14 |
| CA2892750A1 (en) | 2014-06-05 |
| SG11201503719WA (en) | 2015-06-29 |
| AU2013352159A1 (en) | 2015-06-04 |
| EP2925351A1 (en) | 2015-10-07 |
| BR112015012414A2 (pt) | 2017-09-12 |
| JP2016501230A (ja) | 2016-01-18 |
| ZA201504659B (en) | 2017-11-29 |
| IL238658A0 (en) | 2015-06-30 |
| TW201429992A (zh) | 2014-08-01 |
| RU2015125349A (ru) | 2017-01-10 |
| HK1212896A1 (zh) | 2016-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR093671A1 (es) | Anticuerpos monoclonales contra una proteina activada c (apc) | |
| CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
| MX2022015901A (es) | Proteinas de union biespecificas y usos de las mismas. | |
| EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
| ECSP14001249A (es) | Inmunoenlazadores dirigidos contra el tnf | |
| EA201490825A1 (ru) | Tdp-43-специфически связывающие молекулы | |
| EA201490677A1 (ru) | Связывающие антиген cd27l белки | |
| CR20130132A (es) | Anticuerpos contra metalproteasa-9 de matriz | |
| EA201201435A1 (ru) | ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| UY33319A (es) | PROTEÍNAS QUE SE UNEN AL TNF-a | |
| EA201890790A1 (ru) | Связывающие pd-1 белки и способы их применения | |
| EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| NZ706377A (en) | Il-6 antagonists and uses thereof | |
| EA201100300A1 (ru) | Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента | |
| ECSP14001260A (es) | Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas | |
| PE20150605A1 (es) | Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico | |
| BRPI0919473A2 (pt) | Agentes de ligação frizzled e usos dos mesmos | |
| MA34004B1 (fr) | Protéines de liaison à cd127 | |
| ECSP15005280A (es) | Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos | |
| EA201491575A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| EA201291065A1 (ru) | Антитела против vla-4 | |
| EA201892097A1 (ru) | АНТИТЕЛА К ФНО-α И ИХ ФУНКЦИОНАЛЬНЫЕ ФРАГМЕНТЫ | |
| EA201690114A1 (ru) | КОНЪЮГАТ Fc ИММУНОГЛОБУЛИНА, СОХРАНЯЮЩИЙ СПОСОБНОСТЬ СВЯЗЫВАНИЯ С FcRn | |
| EA202090084A1 (ru) | Новый терапевтический ферментный слитый белок и его применение | |
| EA202191656A1 (ru) | Анти-il-36 антитела и способы их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |